Relative survival of patients with lymphoma in Queensland according to histological subtype
| العنوان: | Relative survival of patients with lymphoma in Queensland according to histological subtype |
|---|---|
| المؤلفون: | Fraser Wright, Julie Moore, Nathan Dunn, Aravi Loganathan, Peter Mollee, Shoni Philpot, Greg Hapgood |
| المصدر: | The Medical Journal of Australia. 209:166-172 |
| بيانات النشر: | Wiley, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Lymphoma, B-Cell, Adolescent, medicine.medical_treatment, Population, Follicular lymphoma, Kaplan-Meier Estimate, Young Adult, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Internal medicine, Epidemiology, medicine, Humans, education, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, education.field_of_study, Relative survival, business.industry, Hazard ratio, General Medicine, Middle Aged, medicine.disease, Lymphoma, 030220 oncology & carcinogenesis, Female, Rituximab, Queensland, business, 030215 immunology, medicine.drug |
| الوصف: | Objective: To evaluate relative survival of patients in Queensland with different lymphoma subtypes; to determine whether outcomes have improved with recent changes in treatment; to evaluate relative survival according to place of residence and socio-economic status. Design: Retrospective population-based study; analysis of data from the Oncology Analysis System, an online reporting tool for cancer incidence and outcomes in Queensland. Participants: Patients over 15 years of age diagnosed with lymphoma in Queensland during 1993−2012. Main outcome measures: Relative survival by lymphoma subtype; influence of place of residence and socio-economic status, age group, sex, year of diagnosis (in 5-year bands), and Pharmaceutical Benefits Scheme funding of rituximab for treating B-cell lymphomas on relative survival. Results: 9509 people (56% men) were diagnosed with lymphoma during 1993−2012. Five-year relative survival improved significantly between 1993−1997 and 2008−2012 for patients with diffuse large B-cell lymphoma (47%; 95% CI, 42−51% v 64%; 95% CI, 61−67%) or follicular lymphoma (62%; 95% CI, 57−66% v 88%; 95% CI, 85−90%; each P < 0.001). Rituximab became available for treating these subtypes during 2003−2006. There was no change in relative survival for patients with Hodgkin lymphoma (81%; 95% CI, 76−85% v 80%; 95% CI, 75−84%; P = 0.22). The only statistically significant difference according to place of residence or socio-economic status was inferior relative survival for rural residents with diffuse large B-cell lymphoma (hazard ratio, 1.14; 95% CI, 1.01−1.28). Conclusion: Relative survival for patients with B-cell non-Hodgkin lymphoma improved significantly with the introduction of rituximab as first-line therapy in Australia. |
| تدمد: | 1326-5377 0025-729X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4007bab0ab84ea08cccc6cc9f6735254 https://doi.org/10.5694/mja17.00937 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....4007bab0ab84ea08cccc6cc9f6735254 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13265377 0025729X |
|---|